MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $5.05 and last traded at $5.09, with a volume of 1174179 shares. The stock had previously closed at $5.11.

Wall Street Analysts Forecast Growth

MDXG has been the subject of a number of research reports. Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Lake Street Capital decreased their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

MiMedx Group Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The business has a 50-day moving average of $6.39 and a 200-day moving average of $6.81. The company has a market capitalization of $753.84 million, a P/E ratio of 18.85 and a beta of 1.57.

Insiders Place Their Bets

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider directly owned 236,982 shares of the company’s stock, valued at $1,758,406.44. This represents a 19.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC boosted its holdings in MiMedx Group by 63.8% during the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after acquiring an additional 1,892 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of MiMedx Group by 1,808.4% during the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of MiMedx Group during the third quarter valued at $54,000. Headlands Technologies LLC purchased a new stake in shares of MiMedx Group during the second quarter valued at $72,000. Finally, Osaic Holdings Inc. grew its holdings in shares of MiMedx Group by 57.2% in the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after purchasing an additional 4,708 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.